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1. Introduction
Inhibitors of glycogen phosphorylase (GP) enzymes have been
considered as possible means for therapeutic intervention in ﬁrst
of all type 2 diabetes but also other diseased states. For the bio-
chemical rationale behind these considerations the reader is kindly
referred to recent review articles.1–6 As part of an ongoing project
to synthesize new glucose derivatives7 for the inhibition of GP N-
acyl-b-D-glucopyranosylamines8 (Chart 1, I: e.g. for R = 2-naphthyl
Ki (against rabbit muscle GPb, RMGPb) 10 lM8 or 13 lM9) as well
as N-acyl-N0-b-D-glucopyranosyl urea derivatives4 II (R = 2-naph-
thyl: Ki (RMGPb) 0.35 lM) have been taken as lead structures.
Non-classical bioisosteric replacement of the NHCO moiety in I
by the heterocyclic linker A revealed high similarity of the amide
(see Ki of I above) and the 1,2,3-triazole type (for IA R = 2-naph-
thyl: Ki (RMGPb) 16 lM9) inhibitors both in binding strength and
structural features of the enzyme–inhibitor complexes.9,10
Applying the isomeric B, C, and D moieties as linkers resulted in
inhibitors of varying efﬁciency,11,12 whereby the 3-aryl-5-b-D-
glucopyranosyl-1,2,4-oxadiazole (ID type) derivatives proved to
be the most potent compounds (for the best inhibitor where
R = 2-naphthyl the Ki (RMGPb) was 2.4 lM12). Very recently we
have reported on the synthesis and enzymatic evaluation of a
0008-6215/$ - see front matter  2012 Elsevier Ltd. All rights reserved.
doi:10.1016/j.carres.2012.01.020
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Please cite this article in press as: Kónya, B.; et al. Carbohydr. Res. (2-1,2,3-triazole-4-carboxamides and N-(b-D-glucopyranosyl)-3-substituted
respectively. These compounds were O-deacetylated by Zemplén’s protoc
rabbit muscle glycogen phosphorylase b. The best inhibitors of the two serie
yl)-1-(3,5-dimethyl-phenyl)-1,2,3-triazole-4-carboxamide (Ki = 34 lM) an
indol-2-yl)-isoxazole-5-carboxamide (Ki = 164 lM).








































D60series of compounds of type II with linker 1 and linker 2 being
1,2,3-triazoles A and F as well as 1,3,4-oxadiazole B in various cou-
pling patterns.13 The best inhibitors against RMGPb were effective
in the upper micromolar range (linker 1 = A, linker 2 = B, R = Ph: Ki





















Herein we report on the synthesis and enzymatic test of some
compounds of type III with isoxazole E and 1,2,3-triazole F as
linkers.
2. Results and discussion
For the preparation of compounds of type IIIE and IIIF construc-
70 tion of the heterocyclic parts by 1,3-dipolar cycloadditions14 of an
alkyne and nitrile-oxides15 as well as azides,16,17 respectively, was
envisaged. As the direct transformation of azide 118 by acylation of
an in situ generated iminophosphorane19 with propiolic acid failed,
the necessary protected N-propynoyl-b-D-glucopyranosylamine 3
was obtained from glucosylamine 220 and propiolic acid by a
DCC-mediated coupling in high yield (Scheme 1).
The copper(I) catalyzed cycloaddition reaction (CuAAC) of 3
with aromatic azides was investigated ﬁrst (Scheme 2). The non-
commercial azides were prepared either in situ from the corre-
80 sponding boronic acids following a recently published procedure21
or from the related aniline derivatives via diazonium salts.22 The
widely used system CuSO4–L-ascorbic acid was applied to generate
the catalyst, and the cycloadducts 4–8 were obtained in high
yields. A trial with a recently published catalyst Cu(PPh3)2NO323
in 2 mol % loading under the same conditions did not signiﬁcantly
improve the yield of 4 (93%).
Alkyne 3 was next transformed with nitrile-oxides which were
oxidatively generated in situ from aromatic aldoximes by using
domestic bleach.24 The target compounds 14–20 were obtained
90 in modest to acceptable yields, among which the indole derivatives
19 and 20 having an NH group could be isolated in the lowest
yields.
O-Acetyl protecting groups were removed by the Zemplén pro-
tocol to give the test compounds 9–13 and 21–27 (Schemes 2 and
3, respectively) in high yields.
Proton and carbon NMR spectra of triazoles 4–13 and isoxazoles
14–27 contained resonances for the sugar part and the amide
moiety of the compounds as expected. In the 13C NMR spectra
signals for the triazole C-4 (quaternary) and C-5 (CH) appeared in
100the 140–143 and 116–121 ppm range, respectively, thereby cor-
roborating the anticipated 1,4-disubstitution pattern of the 1,2,3-
triazole in analogy with previously reported compounds.10 The
isoxazole C(4)–H appeared in the 7.2–7.3 ppm range for the pro-
tected derivatives 14–20, and in the 7.5–7.9 ppm range for the
unprotected 21–27. HMBC spectra allowed to identify isoxazole
C3 (155–163 ppm) and C5 (162–166 ppm) resonances in the whole
















































Ar                                     R = Ac            R = H
Ph                  14 (55 %)       21 (97 %)        
2-Naphthyl                       15 (52 %)       22 (91 %)
Benzo-[b]-furan-2-yl         16 (50 %)       23 (88 %)
Benzo-[b]-thiophen-2-yl   17 (51 %)       24 (95 %)
Benzothiazol-2-yl             18 (30 %)       25 (90 %) 
Indol-2-yl           19 (24 %)       26 (76 %)
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Schemease cite this article in press as: Kónya, B.; et al. Carbohydr. Res. (2012),ole C–H and both the amide CO and a quaternary carbon of the
omatic substituent indicated the formation of 3-aryl-isoxazole-
carboxamides 14–20 (contrary to the possibility of 3-aryl-isox-
ole-4-carboxamide derivatives).
The heterocyclic N-(b-D-glucopyranosyl) carboxamides were
sted for their inhibitory activity against rabbit muscle glycogen
osphorylase b as described earlier,8 and the obtained data, to-
ther with some relevant literature values, are collected in Table
The triazole derivatives 9 and 11–13 had inhibitor constants in
e micromolar range. The inactivity of the 2-naphthyl compound
2O (5 mol%)
cid (15 mol%)














Ar                        R = Ac              R = H
Ph                       4 (91 %)             9 (88 %)
2-Naphthyl          5 (75 %)           10 (61 %)
3,5-di-Me-C6H3 6 (78%)            11 (87 %)
4-CF3-C6H4 7 (79 %)           12 (70 %)
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8 February 201210 was surprising especially in the light of very strong inhibitio
by 2-naphthyl derivatives in other series of glucose based inhib
tors,7 for example, acyl ureas 28–32 from which 29 had the highes
afﬁnity. While in these latter cases the inhibition became stronge
with increasing size of the aromatic part of the molecules, this ten
dency seemed to be reversed among triazoles 9–13. The relativel
weak binding of a more or less similar triazole derivative 33 wa
attributed to the diminished number of interactions of the inhib
tor with the protein as well as to the steric bulk of the aglycon
inducing unfavorable changes in the vicinity of the binding sit
(more speciﬁcally the so-called 280s loop next to the catalyt
center).25 The present observations might have a similar origin
In addition, the bioisosteric relationship of the amide and th
1,2,3-triazole moieties, which proved to be valid for N-acyl-b-D
glucopyranosylamines and 1-b-D-glucopyranosyl-4-substituted
1,2,3-triazoles9 outlined in the introduction, cannot be justiﬁe
for the case of the ‘second’ NHCO group of the N-acyl-N0-b-D-gluco
pyranosyl urea type GP inhibitors.
Inhibition of RMGPb by the isoxazoles 21–27 was even weake
Thus, phenyl-isoxazole 21 had a more than twice less afﬁnity tha
its triazole counterpart 9. An increase in the size of the aromat
moiety as in compounds 22–25 resulted in a complete loss of activ
ity. Interestingly, the indole derivatives 26 and 27, in which th
steric bulk of the rings must be essentially the same as in 23–25
showed weak binding similar to that of 21. This might be due t
the hydrogen bond donor capacity of this ring system. It can als
be envisaged that these compounds bind to the so-called new
Table 1








































a Calculated from the IC50 values by the Cheng–Prusoff equation29: Ki = IC50/(1Please cite this article in press as: Kónya, B.; et al. Carbohydr. Res. (2allosteric (or indole binding) site of the enzyme where some glu
cose derivatives were also shown to be accommodated.4,26,27 Thes
points need further investigations.
In summary, 1,3-dipolar cycloadditions of aromatic azides an
nitrile-oxides were used as the key steps in the synthesis of N
(b-D-glucopyranosyl)-1-substituted-1,2,3-triazole-4-carboxamide
and N-(b-D-glucopyranosyl)-3-substituted-isoxazole-5-carboxam
ides, respectively. The new compounds inhibited rabbit muscl
glycogen phosphorylase b in the low micromolar range. Th
amide-1,2,3-triazole bioisosterism could not be veriﬁed for th
‘second’ NHCO part of N-acyl-N0-b-D-glucopyranosyl ureas.
3. Experimental
3.1. General methods
Melting points were measured in open capillary tubes or on
Koﬂer hot-stage and are uncorrected. Optical rotations were deter
mined on a Perkin–Elmer 241 polarimeter at room temperatur
NMR spectra were recorded with Bruker WP 360 SY (360/90 MH
for 1H/13C) and Varian UNITYINOVA 400 WB (400/100 MHz fo
1H/13C) spectrometers. Chemical shifts are referenced to Me4Si a
the internal reference (1H) or the residual solvent signal (13C
Thin-layer chromatography (TLC) was carried out on aluminum
sheets coated with Silica Gel 60 F254 (Merck). TLC plates were in
spected by UV light (k = 254 nm) and after gentle heating for th






















2a 22 no inhibition 23 X = O
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Plrformed with Silica Gel Si 60 (40–63 lm) purchased from Merck
armstadt, Germany). Organic solutions were dried over anhy-
ous MgSO4, and concentrated at diminished pressure at 40–
C (water bath). Aromatic aldoximes were prepared in the usual




2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosylamine20 (2, 1 g,
82 mmol) was dissolved in dry CH2Cl2 (20 mL), propiolic acid
55 lL, 2 equiv) and DCC (0.565 g, 1.05 equiv) were added. The
ixture was stirred at rt and monitored by TLC (1:1 EtOAc–hex-
e). After consumption of the amine the solvent was evaporated
d the residue was puriﬁed by column chromatography (eluent:
1 EtOAc–hexane) to give 1.01 g (88%) yellow syrup. Rf = 0.5
:1 EtOAc–hexane); [a]D 31 (c 0.22, CHCl3); 1H NMR (CDCl3,
0 MHz) d (ppm) 7.27 (d, 1H, J = 9.0 Hz, NH), 5.20 (t, 1H, J = 9.4,
Hz, H-1), 5.03–4.80 (m, 2H, H-3, H-4), 4.19 (dd, 1H, J = 12.0,
Hz, H-6a), 4.00 (m, 2H, H-2, H-6b), 3.76 (ddd, 1H, J = 9.2, 5.0,
Hz, H-5), 2.97 (s, 1H, CH), 1.97, 1.95, 1.92, 1.91 (m, 12H,
CH3); 13C NMR (CDCl3, 90 MHz) d (ppm) 171.4, 171.3, 170.6,
0.3 (4xOCOCH3), 153.0 (NHCO), 78.3 (C-1), 77.2 (CCH), 74.3,
.6, 71.0, 68.7 (C-2–C-5), 61.1 (C-6), 49.7 (CCH), 21.7, 21.4 21.2,
.2 (4  OCOCH3). Anal. Calcd for C17H21NO10 (399.35): C, 51.13;
5.30; N, 3.51. Found: C, 51.33; H, 5.12; N, 3.41.
. General procedure for the Zemplén deacylation
An O-peracylated compound (100 mg) was dissolved in dry
eOH (1 mL) and a solution of NaOMe (1 M in MeOH) was added
the solution in a catalytic amount. The reaction mixture was
pt at rt. When the reaction was complete (TLC, 7:3 CHCl3–MeOH)
e solution was neutralized with a cation exchange resin Amber-
t 15 (H+ form). Filtration and removal of the solvent resulted in
e corresponding deacetylated sugar derivative which, if neces-
ry, was puriﬁed by column chromatography.
. General procedures for the Cu(I) catalyzed azide–alkyne
cloaddition
.1. In CH2Cl2–water mixtures with organic azides
Equimolar amounts of N-propynoyl-2,3,4,6-tetra-O-acetyl-b-D-
copyranosylamine (3) and an azide were dissolved in CH2Cl2
mL/mmol alkyne). Water (the same volume as that of CH2Cl2),
SO45H2O (5 mol %), L-ascorbic-acid (15 mol %) were added and
e mixture was stirred at 50 C and monitored by TLC (1:1
OAc–hexane). After disappearance of the starting materials the
action mixture was diluted with water and CH2Cl2, the phases
re separated, and the aqueous layer was washed with CH2Cl2
 10 mL/mmol). The combined organic layer was dried, the sol-
nt evaporated, and the residue puriﬁed by column chromatogra-
y (eluent: 1:1 EtOAc–hexane).
.2. In CH2Cl2–water mixtures with organic azides prepared
situ from boronic acids
Boronic acid (1 equiv) and NaN3 (1.2 equiv) were dissolved in
eOH (5 mL/mmol of boronic acid). CuSO45H2O (0.10 equiv)
s added and the mixture was stirred overnight at rt. CH2Cl2
d water (10 mL of each/mmol of boronic acid), N-propynoyl-
,4,6-tetra-O-acetyl-b-D-glucopyranosylamine (3, 0.75 equiv)
d L-ascorbic acid (0.5 equiv) were added and the reaction mix-
re was heated to 50 C. After consumption of the alkyne (TLC,
1 EtOAc–hexane) the reaction mixture was diluted with water
d CH2Cl2, the phases were separated and the aqueous layer
(4
49
ease cite this article in press as: Kónya, B.; et al. Carbohydr. Res. (2012),s washed with CH2Cl2 (2  10 mL/mmol). The combined organic
er was dried, the solvent evaporated, and the residue puriﬁed by
lumn chromatography (eluent: 1:1 EtOAc–hexane).
.3. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-1-phenyl-
,3-triazole-4-carboxamide (4)
Prepared by general procedure given in Section 3.4.1 from 3
35 mg, 0.841 mmol) and PhN3 for 1 day. Yield: 396 mg (91%)
ite crystals. Rf = 0.43 (1:1 EtOAc–hexane); Mp: 232–234 C
]D 6.9 (c 0.54, DMSO) 1H NMR (DMSO-d6, 360 MHz) d (ppm)
9 (s, 1H, triazole CH), 9.37 (br s, 1H, NH), 7.97 (d, 2H,
7.6 Hz, ArH), 7.64–7.54 (m, 3H, ArH), 5.66 (t, 1H, J = 9.1,
Hz, H-1), 5.41, 5.24, 4.92 (3 pseudo t, J = 9.1, 10.6 Hz in each,
2, H-3, H-4), 4.19–4.44 (m, 2H, H-6a, H-5), 4.01 (dd, 1H,
11.9, 3.0 Hz, H-6b), 2.01, 2.01, 1.95, 1.91 (4s, 12H, 4  CH3);
NMR (DMSO-d6, 90 MHz) d (ppm) 171.0, 170.8, 169.9, 169.0
O), 157.3 (NHCO), 140.8 (triazole C-4), 129.2, 128.8, 128.8,
8.5, 125.5, 125.5 (Ar), 116.7 (triazole C-5), 78.1 (C-1), 73.9,
.1, 70.6, 68.5 (C-2–C-5), 62.0 (C-6), 20.3, 20.2, 20.0 (CH3). Anal.
lcd for C23H26N4O10 (518.47): C, 53.28; H, 5.05; N, 10.81. Found:
52.88; H, 4.86; N, 10.94.
.4. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-1-(2-
phthyl)-1,2,3-triazole-4-carboxamide (5)
Prepared by general procedure given in Section 3.4.2 from 3
96 mg, 1.744 mmol) and 2-naphthylazide (prepared in situ from
phthalene-2-boronic acid (300 mg, 1.744 mmol)). Yield: 743 mg
5%) white crystals. Rf = 0.33 (1:1 EtOAc–hexane); Mp: 223–
5 C [a]D 1.1 (c 0.27, DMSO) 1H NMR (CDCl3, 360 MHz) d
pm) 8.61 (s, 1H, triazole CH), 8.14 (br s, 1H, NH), 7.89 (m, 5H,
H), 7.55–7.52 (m, 2H, ArH), 5.45 (t, 1H, J = 9.3, 9.3 Hz, H-1),
1, 5.11, 5.10 (3 pseudo t, 1H each, J = 9.5, 10.5 Hz in each, H-2,
3, H-4), 4.25 (dd, 1H, J = 12.2, 3.8 Hz, H-6a), 4.08 (dd, 1H,
12.2, 1.9 Hz, H-6b), 3.85 (m, 1H, H-5), 2.03, 1.99, 1.98, 1.96
s, 12H, 4  CH3); 13C NMR (CDCl3, 90 MHz) d (ppm) 170.8,
0.5, 170.2, 169.7 (CO), 160.3 (NHCO), 142.8 (triazole C-4),
3.9, 133.3, 130.5 128.5, 128.1, 127.9, 127.6, 119.2 (Ar), 118.8 (tri-
ole C-5), 78.1 (C-1), 73.8, 73.2, 70.6, 68.3 (C-2–C-5), 61.8 (C-6),
.9, 20.7 (CH3). Anal. Calcd for C27H28N4O10 (568.53): C, 57.04;
4.96; N, 9.85. Found: C, 56.64; H, 4.77; N, 9.98.
.5. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-1-(3,5-
methyl-phenyl)-1,2,3-triazole-4-carboxamide (6)
Prepared by general procedure given in Section 3.4.2 from 3
98 mg, 2.00 mmol) and 3,5-dimethyl-phenyl-azide (prepared
situ from 3,5-dimethyl-phenylboronic acid (300 mg,
0 mmol)). Yield: 852 mg (78%) yellow syrup. Rf = 0.48 (1:1
OAc–hexane) [a]D 29 (c 0.34, CHCl3) 1H NMR (CDCl3,
0 MHz) d (ppm) 8.49 (s, 1H, triazole CH), 7.94 (d, 1H, J = 9.5 Hz,
), 7.32 (s, 2H, ArH), 7.09 (s, 1H, ArH), 5.49 (t, 1H, J = 9.5,
Hz, H-1), 5.37, 5.16, 5.13 (3 pseudo t, 1H each, J = 9.5, 10.1 Hz
each, H-2, H-3, H-4), 4.30 (dd, 1H, J = 11.9, 4.0 Hz, H-6a), 4.13
d, 1H, J = 11.9, 1.9 Hz, H-6b), 3.90 (m, 1H, H-5), 2.39 (s, 6H,
CH3), 2.07, 2.03, 2.02, 1.99 (4s, 12H, 4  CH3); 13C NMR (CDCl3,
MHz) d (ppm) 170.8, 170.4, 170.2, 169.6 (CO), 160.4 (NHCO),
2.4 (triazole C-4), 140.1, 136.4, 136.4, 131.2, 131.2, 124.3 (Ar),
8.8 (triazole C-5), 78.0 (C-1), 73.7, 73.1, 70.5, 68.2 (C-2–C-5),
.8 (C-6), 21.4, 21.4 (CH3), 20.8, 20.7 (CH3). Anal. Calcd for
5H30N4O10 (546.53): C, 54.94; H, 5.53; N, 10.25. Found: C,
.54; H, 5.34; N, 10.38.
.6. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-1-(4-
ﬂuoromethyl-phenyl)-1,2,3-triazole-4-carboxamide (7)
Prepared by general procedure given in Section 3.4.1 from 3
26 mg, 1.069 mmol) and 4-CF3–C6H4–N3 for 1 day. Yield:
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8 February 20121.2 (c 0.30, DMSO) 1H NMR (CDCl3, 360 MHz) d (ppm) 8.77 (s, 1H
triazole CH), 8.12 (d, 1H, J = 9.5 Hz, NH), 7.97 (d, 2H, J = 8.4 H
ArH), 7.83 (d, 2H, J = 8.4 Hz, ArH), 5.56 (t, 1H, J = 9.4, 9.4 Hz, H-1
5.40 (t, 1H, J = 9.7, 9.7 Hz, one of H-2, H-3, H-4), 5.18–5.05 (m
2H, two of H-2, H-3, H-4), 4.30 (dd, 1H, J = 11.2, 4.0 Hz, H-6a
4.10 (dd, 1H, J = 11.2, 4.0 Hz, H-6b), 3.96 (m, 1H, H-5), 2.05, 2.02
2.00, 1.98 (4s, 12H, 4  CH3); 13C NMR (CDCl3, 90 MHz) d (ppm
170.7, 170.5, 170.0, 169.9 (CO), 160.0 (NHCO), 143.0 (triazole C
4), 138.8, 131.2 (q, C–CF3, J = 34.9 Hz), 127.3, 126.0, 124.9, 124.
(Ar), 121.9 (q, CF3, J = 277 Hz), 120.8 (triazole C-5), 77.9 (C-1
73.7, 73.0, 70.5, 68.2 (C-2–C-5), 61.7 (C-6), 20.7, 20.6 (CH3). Ana
Calcd for C24H25F3N4O10 (586.47): C, 49.15; H, 4.30; N, 9.55. Found
C, 48.75; H, 4.11; N, 9.69.
3.4.7. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-1-(4-tbuty
phenyl)-1,2,3-triazole-4-carboxamide (8)
Prepared by general procedure given in Section 3.4.1 from
(456 mg, 1.143 mmol) and 4-tBu–C6H4–N3 for 1 day. Yield
558 mg (85%) white crystals. Rf = 0.49 (1:1 EtOAc–hexane); Mp
194–196 C [a]D 5.4 (c 0.33, DMSO) 1H NMR (CDCl3, 360 MHz)
(ppm) 8.55 (s, 1H, triazole CH), 8.00 (d, 1H, J = 9.5 Hz, NH), 7.6
(d, 2H, J = 8.6 Hz, ArH), 7.51 (d, 2H, J = 8.6 Hz, ArH), 5.52 (t, 1H
J = 9.5, 9.5 Hz, H-1), 5.36, 5.16, 5.10 (3 pseudo t, 1H each, J = 9.5
9.5 Hz in each, H-2, H-3, H-4), 4.26 (dd, 1H, J = 11.2, 4.0 Hz, H
6a), 4.08 (dd, 1H, J = 11.2, 2.1 Hz, H-6b), 3.90 (m, 1H, H-5), 2.02
1.99, 1.99, 1.96 (4s, 12H, 4  CH3), 1.31 (s, 9H, C(CH3)3); 13C NM
(CDCl3, 90 MHz) d (ppm) 170.7, 170.3, 170.1, 169.5 (CO), 160.
(NHCO), 152.9 (Ar), 142.5 (triazole C-4), 134.0, 126.8, 126.8
124.2, 124.2 (Ar), 120.4 (triazole C-5), 77.8 (C-1), 73.6, 73.1, 70.5
68.2 (C-2–C-5), 61.8 (C-6), 34.9 (C(CH3)3), 31.2 (C(CH3)3), 20.7
20.6 (CH3). Anal. Calcd for C27H34N4O10 (574.58): C, 56.44; H
5.96; N, 9.75. Found: C, 56.20; H, 5.76; N, 9.94.
3.4.8. N-(b-D-Glucopyranosyl)-1-phenyl-1,2,3-triazole-4-
carboxamide (9)
Prepared by general procedure given in Section 3.3 from
(200 mg, 0.386 mmol) for 1 h. Yield: 119 mg (88%) white crystal
Rf = 0.53 (7:3 CHCl3–MeOH); Mp: 199–201 C [a]D +3.4 (c 0.15
DMSO) 1H NMR (DMSO-d6 + D2O, 360 MHz) d (ppm) 9.38 (s, 1H
triazole CH), 7.98 (d, 2H, J = 7.6 Hz, ArH), 7.58 (m, 3H, ArH), 4.8
(d, 1H, J = 8.9 Hz, H-1), 3.67 (dd, 1H, J = 12.3, 2.9 Hz, H-6a), 3.25
3.09 (m, 5H, H-2, H-3, H-4, H-5, H-6b); 13C NMR (DMSO
d6 + D2O, 90 MHz) d (ppm) 160.7 (NHCO), 143.4 (triazole C-4
133.3, 131.7, 128.7, 127.9 (Ar), 118.4 (triazole C-5), 80.0 (C-1
72.9, 71.2 70.1, 68.9 (C-2–C-5), 62.2 (C-6). Anal. Calcd fo
C15H18N4O6 (350.33): C, 51.43; H, 5.18; N, 15.99. Found: C, 51.01
H, 4.98; N, 16.05.
3.4.9. N-(b-D-Glucopyranosyl)-1-(2-naphthyl)-1,2,3-triazole-4-
carboxamide (10)
Prepared by general procedure given in Section 3.3 from
(180 mg, 0.317 mmol) for 2 h. Yield: 77 mg (61%) white crystal
Rf = 0.51 (7:3 CHCl3–MeOH); Mp: 275–277 C (decomp.) [a]D +4.
(c 0.34, DMSO) 1H NMR (DMSO-d6 + D2O, 360 MHz) d (ppm) 9.3
(s, 1H, triazole CH), 8.50 (s, 1H, ArH), 8.17 (d, 1H, J = 8.9 Hz, ArH
8.12–7.98 (m, 3H, ArH), 7.69–7.59 (m, 2H, ArH), 4.95 (d, 1H
J = 9.0 Hz, H-1), 3.66 (dd, 1H, J = 10.9, 2.0 Hz, H-6a), 3.50–3.33 (m
2H, H-3, H-6b), 3.29–3.10 (m, 3H, H-2, H-4, H-5); 13C NM
(DMSO-d6 + D2O, 90 MHz) d (ppm) 160.3 (NHCO), 142.0 (triazol
C-4), 134.6, 131.9, 129.6, 129.4, 128.0, 127.7, 127.1, 124.4 (Ar
119.1 (triazole C-5), 80.2 (C-1), 72.1, 71.3 70.1, 68.7 (C-2–C-5
62.1 (C-6). Anal. Calcd for C19H20N4O6 (400.39): C, 57.00; H, 5.03
N, 13.99. Found: C, 56.60; H, 4.86; N, 14.04.Please cite this article in press as: Kónya, B.; et al. Carbohydr. Res. (23.4.10. N-(b-D-Glucopyranosyl)-1-(3,5-dimethyl-phenyl)-1,2,3-
triazole-4-carboxamide (11)
Prepared by general procedure given in Section 3.3 from
(180 mg, 0.317 mmol) for 1 h. Yield: 104 mg (87%) white crystal
Rf = 0.74 (7:3 CHCl3–MeOH); Mp: 145–147 C [a]D +1.7 (c 0.33
DMSO) 1H NMR (DMSO-d6 + D2O, 360 MHz) d (ppm) 9.15 (s, 1H
triazole CH), 7.52 (s, 2H, ArH), 7.15 (s, 1H, ArH), 4.93 (d, 1H
J = 9.0 Hz, H-1), 3.65 (dd, 1H, J = 11.0, 2.1 Hz, H-6a), 3.51–3.32 (m
2H, H-3, H-6b), 3.31–3.12 (m, 3H, H-2, H-4, H-5), 2.34 (s, 6H
2xCH3); 13C NMR (DMSO-d6 + D2O, 90 MHz) d (ppm) 160.7 (NHCO
143.3 (triazole C-4), 140.2, 136.5, 133.2, 127.1, 126.4, 126.0 (Ar
118.3 (triazole C-5), 80.0 (C-1), 72.7, 71.2, 70.3, 68.8 (C-2–C-5
61.9 (C-6). Anal. Calcd for C17H22N4O6 (378.38): C, 53.96; H, 5.86
N, 14.81. Found: C, 53.56; H, 5.73; N, 14.94.
3.4.11. N-(b-D-Glucopyranosyl)-1-(4-triﬂuoromethyl-phenyl)-
1,2,3-triazole-4-carboxamide (12)
Prepared by general procedure given in Section 3.3 from
(200 mg, 0.341 mmol) for 2 h. Yield: 100 mg (70%) white crystal
Rf = 0.57 (7:3 CHCl3–MeOH); Mp: 241–243 C [a]D +4.5 (c 0.6
DMSO) 1H NMR (DMSO-d6 + D2O, 360 MHz) d (ppm) 9.35 (s, 1H
triazole CH), 8.16 (d, 2H, J = 8.3 Hz, ArH), 7.98 (d, 2H, J = 8.6 H
ArH), 4.94 (d, 1H, J = 9.0 Hz, H-1), 3.64 (dd, 1H, J = 12.9, 2.4 Hz, H
6a), 3.41–3.35 (m, 2H, H-3, H-6b), 3.29–3.06 (m, 3H, H-2, H-4, H
5); 13C NMR (DMSO-d6 + D2O, 90 MHz) d (ppm) 160.5 (NHCO
143.8 (triazole C-4), 139.4, 130.0, 129.7 (q, C–CF3, J = 30.4 Hz
128.0, 127.7, (Ar), 122.7 (q, CF3, J = 273.2 Hz), 116.7 (triazole C-5
80.0 (C-1), 72.4, 71.3, 70.4, 69.0 (C-2, C-3, C-4, C-5), 62.0 (C-6
Anal. Calcd for C16H17F3N4O6 (418.32): C, 45.94; H, 4.10; N
13.39. Found: C, 45.54; H, 3.91; N, 13.53.
3.4.12. N-(b-D-Glucopyranosyl)-1-(4-tbutyl-phenyl)-1,2,3-
triazole-4-carboxamide (13)
Prepared by general procedure given in Section 3.3 from
(200 mg, 0.348 mmol) for 2 hour. Yield: 111 mg (79%) white crys
tals. Rf = 0.62 (7:3 CHCl3–MeOH); Mp: 207–209 C [a]D +1.9 (c 0.34
DMSO) 1H NMR (DMSO-d6 + D2O, 360 MHz) d (ppm) 9.06 (s, 1H
triazol CH), 7.75 (d, 2H, J = 8.4 Hz, ArH), 7.58 (d, 2H, J = 8.5 H
ArH), 4.94 (d, 1H, J = 8.9 Hz, H-1), 3.65 (dd, 1H, J = 11.4, 2.3 Hz, H
6a), 3.51–3.34 (m, 2H, H-3, H-6b), 3.23 (m, 3H, H-2, H-4, H-5
1.25 (s, 9H, C(CH3)3); 13C NMR (DMSO-d6 + D2O, 90 MHz) d (ppm
161.5 (NHCO), 153.4 (Ar), 143.5 (triazole C-4), 134.5, 127.9
127.6, 121.4, 121.1 (Ar), 120.2 (triazole C-5), 80.3 (C-1), 72.1
71.2, 70.3, 69.1 (C-2–C-5), 61.9 (C-6), 35.4 (C(CH3)3), 31.
(C(CH3)3). Anal. Calcd for C19H26N4O6 (406.43): C, 56.15; H, 6.45
N, 13.79. Found: C, 55.78; H, 6.25; N, 13.95.3.5. General procedure for the nitrile-oxide cycloaddition
A solution of N-propynoyl-2,3,4,6-tetra-O-acetyl-b-D-glucopyr
anosyl-amine (0.5 mmol) and an arenecarbaldoxime (0.55 mmo
1.1 equiv) in THF (4 mL) was stirred at rt under Argon. 0.2 M NaOC
solution (20 mL) was slowly added dropwise in 5 h with a syring
pump. The reaction was stirred at rt for an additional 12 h, then th
reaction mixture was diluted with water and EtOAc, the phase
were separated and the aqueous layer was washed with EtOA
(2  30 mL/mmol). The combined organic layer was dried, the so
vent evaporated, and the residue puriﬁed by column chromatogra
phy (eluent: 2:3 EtOAc–hexane).
3.5.1. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-3-phenyl-
isoxazole-5-carboxamide (14)
Prepared by general procedure given in Section 3.5 from
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Pleld: 177 mg (55%) white crystals. Rf = 0.31 (2:3 EtOAc–hexane);
p: 212–214 C [a]D 4 (c 0.21, CHCl3) 1H NMR (CDCl3,
0 MHz) d (ppm) 7.82–7.79 (m, 2H, ArH), 7.41 (d, 1H, J = 9.2 Hz,
), 7.40–7.35 (m, 3H, ArH), 7.20 (s, 1H, isoxazole CH), 5.37,
2, 5.07 (3 pseudo t, 4H, J = 9.5, 9.5 Hz in each, H-1, H-2, H-3,
4), 4.30 (dd, 1H, J = 11.9, 2.8 Hz, H-6a), 4.14 (dd, 1H, J = 12.6,
Hz, H-6b) 3.82 (ddd, 1H, J = 9.2, 4.0, 2.6 Hz, H-5), 2.01, 1.98
s, 12H, 4  CH3); 13C NMR (CDCl3, 90 MHz) d (ppm) 170.9,
0.7, 170.0, 169.6 (CO), 165.5 (isoxazole C-5), 162.6 (isoxazole
3), 156.1 (NHCO), 130.8, 129.2, 129.2, 127.9, 127.0, 127.0 (Ar),
6.4 (isoxazole CH), 78.2 (C-1), 74.0, 72.8, 70.6, 68.2 (C-2–C-5),
.7 (C-6), 20.8, 20.7 (OCOCH3). Anal. Calcd for C24H26N2O11




Prepared by general procedure given in Section 3.5 from 3
88 mg, 0.972 mmol) and naphthalene-2-carbaldoxime (200 mg,
69 mmol). Yield: 288 mg (52%) white crystals. Rf = 0.40 (2:3
OAc–hexane); Mp: 202–204 C [a]D 7.8 (c 0.24, CHCl3) 1H
R (CDCl3, 360 MHz) d (ppm) 8.12 (s, 1H, ArH), 7.83–7.76 (m,
, ArH), 7.62 (d, 1H, J = 9.2 Hz, NH), 7.46–7.43 (m, 2H, ArH),
1 (s, 1H, isoxazole CH), 5.42, 5.34, 5.12, 5.08 (4 pseudo t, 4H,
9.2, 9.5 Hz in each, H-1, H-2, H-3, H-4), 4.32 (dd, 1H, J = 11.9,
Hz, H-6a), 4.14 (dd, 1H, J = 11.9, 2.8 Hz, H-6b) 3.89 (ddd, 1H,
9.2, 5.1, 2.8 Hz, H-5), 2.00, 1.99, 1.98, 1.96 (4s, 12H, 4  CH3);
NMR (CDCl3, 90 MHz) d (ppm) 171.2, 171.0, 170.4, 170.0
O), 163.7 (isoxazole C-5), 163.0 (isoxazole C-3), 156.5 (NHCO),
4.6, 133.5, 129.4, 128.9, 128.2, 127.8, 127.4, 127.3, 125.5, 124.0
r), 106.8 (isoxazole CH), 78.5 (C-1), 74.2, 73.2, 70.9, 68.5 (C-2–
5), 62.1 (C-6), 21.1, 21.0 (CH3). Anal. Calcd for C28H28N2O11




Prepared by general procedure given in Section 3.5 from 3
00 mg, 0.501 mmol) and benzo-[b]-furan-2-carbaldoxime
9 mg, 1.551 mmol). Yield: 141 mg (50%) yellow oil. Rf = 0.39
:3 EtOAc–hexane) [a]D 6.7 (c 0.45, CHCl3) 1H NMR (CDCl3,
0 MHz) d (ppm) 7.62–7.55 (m, 2H, ArH), 7.47 (d, 1H, J = 9.2 Hz,
), 7.32–7.19 (m, 3H, ArH, isoxazole CH), 5.40, 5.33, 5.10, 5.08
pseudo t, 4H, J = 9.2, 9.5 Hz in each, H-1, H-2, H-3, H-4), 4.27
d, 1H, J = 12.1, 5.2 Hz, H-6a), 4.06 (dd, 1H, J = 12.1, 2.8 Hz, H-
), 3.84 (ddd, 1H, J = 9.2, 5.2, 2.8 Hz, H-5), 2.01, 1.99, 1.98, 1.96
s, 12H, 4  CH3); 13C NMR (CDCl3, 90 MHz) d (ppm) 170.9,
0.7, 170.0, 169.6 (CO), 162.6 (isoxazole C-5), 156.0 (isoxazole
3), 155.7 (NHCO), 155.4, 144.5, 127.8, 126.4, 123.8, 122.0 (Ar),
6.3 (isoxazole CH), 78.2 (C-1), 74.0, 72.9, 70.6, 68.2 (C-2–C-5),
.7 (C-6), 20.8, 20.7 (CH3). Anal. Calcd for C26H26N2O12 (558.49):
55.91; H, 4.69; N, 5.02. Found: C, 55.50; H, 4.50; N, 5.18.
.4. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-3-(benzo-
]-thiophen-2-yl)-isoxazole-5-carboxamide (17)
Prepared by general procedure given in Section 3.5 from 3
04 mg, 0.513 mmol) and benzo-[b]-thiophen-2-carbaldoxime
00 mg, 0.564 mmol). Yield: 151 mg (51%) yellow crystals.
= 0.29 (2:3 EtOAc–hexane); Mp: 192–194 C (decomp.) [a]D 7
0.21, CHCl3) 1H NMR (CDCl3, 360 MHz) d (ppm) 7.77 (d, 1H,
9.3 Hz, NH), 7.70–7.68 (m, 2H, ArH), 7.59 (s, 1H, ArH), 7.32–
9 (m, 2H, ArH), 7.21 (s, 1H, isoxazole CH), 5.40, 5.33, 5.11,
7 (4 pseudo t, 4H, J = 9.2, 9.5 Hz in each, H-1, H-2, H-3, H-4),
2 (dd, 1H, J = 12.0, 2.9 Hz, H-6a), 4.13 (dd, 1H, J = 12.0, 5.3 Hz,
6b), 3.90 (ddd, 1H, J = 9.2, 5.3, 2.9 Hz, H-5), 2.00, 1.99, 1.98, H,
ease cite this article in press as: Kónya, B.; et al. Carbohydr. Res. (2012),6 (4s, 12H, 4  CH3); 13C NMR (CDCl3, 90 MHz) d (ppm) 171.0,
0.8, 170.0, 169.6 (CO), 162.7 (isoxazole C-5), 159.0 (isoxazole
3), 155.9 (NHCO), 129.3, 126.2, 125.6, 125.0, 124.5, 122.6 (Ar),
6.4 (isoxazole CH), 78.2 (C-1), 73.9, 72.9, 70.6, 68.2 (C-2–C-5),
.8 (C-6), 20.8, 20.7, 20.6 (CH3). Anal. Calcd for C26H26N2O11S




Prepared by general procedure given in Section 3.5 from 3
00 mg, 0.501 mmol) and benzo-[b]-thiazol-2-carbaldoxime
8 mg, 0.551 mmol). Yield: 86 mg (30%) white crystals. Rf = 0.39
:3 EtOAc–hexane); Mp: 179–181 C [a]D 7.6 (c 0.19, CHCl3)
NMR (CDCl3, 360 MHz) d (ppm) 8.10 (d, 1H, J = 9.2 Hz, NH)
1 (m, 2H, ArH), 7.59–7.52 (m, 2H, ArH), 7.27 (s, 1H, isoxazole
), 5.47, 5.39, 5.18, 5.14 (4 pseudo t, 4H, J = 9.2, 9.6 Hz each, H-
H-2, H-3, H-4), 4.38 (dd, 1H, J = 11.9, 5.3 Hz, H-6a), 4.17 (dd,
, J = 11.9, 2.8 Hz, H-6b), 3.94 (ddd, 1H, J = 9.2, 5.3, 2.8 Hz, H-5),
6, 2.06, 2.04, 2.03 (4s, 12H, 4  CH3); 13C NMR (CDCl3,
MHz) d (ppm) 171.0, 170.8, 170.0, 169.6 (CO), 162.4 (isoxazole
5), 161.1 (benzothiazole C-2), 158.3 (isoxazole C-3), 156.3
HCO), 152.5, 136.3, 126.9, 125.5, 123.7, 122.7 (Ar), 102.8 (isoxaz-
CH), 78.0 (C-1), 73.8, 72.6, 71.0, 68.8 (C-2–C-5), 61.8 (C-6), 20.8,
.7, 20.6 (CH3). Anal. Calcd for C25H25N3O11S (575.54): C, 52.17; H,
8; N, 7.30. Found: C, 51.87; H, 4.20; N, 7.45.
.6. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-3-(indol-2-
-isoxazole-5-carboxamide (19)
Prepared by general procedure given in Section 3.5 from 3
00 mg, 0.752 mmol) and indol-2-carbaldoxime (132 mg,
27 mmol). Yield: 100 mg (24%) yellow oil. Rf = 0.44 (2:3
OAc–hexane) [a]D 8.1 (c 0.23, CHCl3) 1H NMR (CDCl3,
0 MHz) d (ppm) 8.24 (s, 1H, indol NH), 7.70–7.41 (m, 5H, ArH, in-
l CH), 7.29 (s, 1H, isoxazole CH), 5.50, 5.42, 5.15, 5.11 (4 pseudo t,
, J = 9.2, 9.6 Hz each, H-1, H-2, H-3, H-4), 4.35 (dd, 1H, J = 11.9,
Hz, H-6a), 4.22 (dd, 1H, J = 11.9, 2.9 Hz, H-6b), 4.00 (ddd, 1H,
9.2, 5.3, 2.9 Hz, H-5), 2.02, 2.00, 1.99, 1.98 (4s, 12H, 4  CH3);
NMR (CDCl3, 90 MHz) d (ppm) 171.2, 170.8, 170.1, 169.5
O), 162.6 (isoxazole C-5), 158.8 (isoxazole C-3), 156.9 (NHCO),
7.1, 135.2, 128.4, 122.6, 121.9, 121.3 118.4 (Ar, indol C-2),
1.0, 100.2 (isoxazole CH, indol CH), 78.1 (C-1), 74.0, 72.7, 71.0,
.4 (C-2–C-5), 61.9 (C-6), 20.5, 20.5, 20.4, 20.4 (CH3). Anal. Calcd
r C26H27N3O11 (557.51): C, 56.01; H, 4.88; N, 7.54. Found: C,
.61; H, 4.69; N, 7.68.
.7. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-3-(indol-3-
-isoxazole-5-carboxamide (20)
Prepared by general procedure given in Section 3.5 from 3
00 mg, 1.00 mmol) and indol-3-carbaldoxime (177 mg,
0 mmol). Yield: 110 mg (20%) yellow oil. Rf = 0.49 (2:3 EtOAc–
xane) [a]D 5.6 (c 0.15, CHCl3) 1H NMR (CDCl3, 360 MHz) d
pm) 7.75 (s, 1H, indol NH), 7.64–7.36 (m, 5H, ArH, indol CH),
8 (s, 1H, isoxazole CH), 5.49, 5.40, 5.17, 5.10 (4 pseudo t, 4H,
9.2, 9.6 Hz each, H-1, H-2, H-3, H-4), 4.24 (dd, 1H, J = 11.9,
Hz, H-6a), 4.19 (dd, 1H, J = 11.9, 3.0 Hz, H-6b), 4.01 (ddd, 1H,
9.2, 5.3, 3.0 Hz, H-5), 2.02, 2.00, 1.99, 1.98 (4s, 12H, 4  CH3);
NMR (CDCl3, 90 MHz) d (ppm) 171.4, 171.2, 170.4, 170.0
O), 164.9 (isoxazole C-5), 160.0 (isoxazole C-3), 156.1 (NHCO),
9.1, 133.0, 125.5, 121.5, 120.0, 119.6 112.8 (Ar, indol C-2),
1.9, 101.0 (isoxazole CH, indol CH), 78.5 (C-1), 73.7, 73.0, 71.1,
.2 (C-2–C-5), 61.5 (C-6), 20.7, 20.6 (CH3). Anal. Calcd for
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8 February 20123.5.8. N-(b-D-Glucopyranosyl)-3-phenyl-isoxazole-5-
carboxamide (21)
Prepared by general procedure given in Section 3.3 from 1
(80 mg, 0.154 mmol) for 1 hour. Yield: 52 mg (97%) white solid
Rf = 0.47 (7:3 CHCl3–MeOH); Mp: 215–217 C (decomp.) [a]D +7.
(c 0.23, DMSO) 1H NMR (DMSO-d6 + D2O, 360 MHz) d (ppm
7.92–7.90 (m, 2H, ArH), 7.80 (s, 1H, isoxazole CH), 7.55–7.53 (m
3H, ArH), 4.88 (t, 1H, J = 9.3, 9.3 Hz, H-1), 3.68–3.35 (m, 3H, H-6
H-2, H-3), 3.27–3.08 (m, 3H, H-6b, H-5, H-4); 13C NMR (DMSO
d6 + D2O, 90 MHz) d (ppm) 164.0 (isoxazole C-5), 162.5 (isoxazol
C-3), 156.2 (NHCO), 130.8, 130.7, 129.4, 129.3, 127.9, 126.7, (Ar
105.0 (isoxazole CH), 80.1 (C-1), 79.0, 77.3, 71.6, 69.9 (C-2–C-5
61.0 (C-6). Anal. Calcd for C16H18N2O7 (350.32): C, 54.86; H, 5.18
N, 8.00. Found: C, 54.47; H, 5.00; N, 8.14.
3.5.9. N-(b-D-Glucopyranosyl)-3-(2-naphthyl)-isoxazole-5-
carboxamide (22)
Prepared by general procedure given in Section 3.3 from 1
(160 mg, 0.281 mmol) for 1.5 h. Yield: 102 mg (91%) white solid.
Rf = 0.51 (7:3 CHCl3–MeOH); Mp: 218–220 C (decomp.) [a]D +6.0
(c 0.25, DMSO) 1H NMR (DMSO-d6 + D2O, 360 MHz) d (ppm) 8.54
(s, 1H, ArH), 8.10–7.99 (m, 4H, ArH), 7.88 (s, 1H, isoxazole CH),
7.65–7.62 (m, 2H, ArH), 5.12–4.93 (m, 4H, H-1, H-2, H-3, H-4),
3.70 (dd, 1H, J = 12.0, 5.0 Hz, H-6a), 3.22 (ddd, 1H, J = 9.0, 5.0,
3.0 Hz, H-5), 3.12 (dd, 1H, J = 12.0, 3.0 Hz, H-6b); 13C NMR
(DMSO-d6 + D2O, 90 MHz) d (ppm) 164.0 (isoxazole C-5), 162.2
(isoxazole C-3), 156.0 (NHCO), 133.8, 132.9, 129.0, 128.6, 128.6,
127.9, 127.6, 127.1, 127.0, 126.9, 125.2, 123.5 (Ar), 105.4 (isoxazole
CH), 79.8 (C-1), 79.0, 77.5, 71.9, 70.0 (C-2–C-5), 61.0 (C-6). Anal.
Calcd for C20H20N2O7 (400.38): C, 60.00; H, 5.03; N, 7.00. Found:
C, 59.64; H, 4.89; N, 7.20.
3.5.10. N-(b-D-Glucopyranosyl)-3-(benzo-[b]-furan-2-yl)-
isoxazole-5-carboxamide (23)
Prepared by general procedure given in Section 3.3 from 16
(120 mg, 0.215 mmol) for 1 h. Yield: 74 mg (88%) yellow solid.
Rf = 0.55 (7:3 CHCl3–MeOH); Mp: 196–198 C [a]D +9 (c 0.18,
DMSO) 1H NMR (DMSO-d6 + D2O, 360 MHz) d (ppm) 7.79–7.72
(m, 4H, ArH, benzofuran CH, isoxazole CH), 7.48–7.33 (m, 2H,
ArH), 4.87 (d, 1H, J = 9.3 Hz, H-1), 3.46–3.10 (m, 6H, H-2, H-3, H-
4, H-5, H-6a, H-6b); 13C NMR (DMSO-d6 + D2O, 90 MHz) d (ppm)
164.0 (isoxazole C-5), 155.0 (isoxazole C-3), 154.9 (NHCO), 154.6
(benzofuran C-2), 145.6, 127.5, 126.6, 123.9, 123.0, 122.4 (Ar),
111.8 (benzofuran C-3), 108.9 (isoxazole CH), 79.9 (C-1), 79.0,
77.4, 71.9, 69.9 (C-2–C-5), 60.9 (C-6). Anal. Calcd for C18H18N2O8




Prepared by general procedure given in Section 3.3 from 17
(120 mg, 0.209 mmol) for 1 h. Yield: 81 mg (95%) yellow solid.
Rf = 0.51 (7:3 CHCl3–MeOH); Mp: 234–236 C [a]D +7.8 (c 0.25,
DMSO) 1H NMR (DMSO-d6 + D2O, 360 MHz) d (ppm) 8.16 (s, 1H,
benzothiophen CH), 8.08–7.95 (m, 2H, ArH), 7.83 (s, 1H, isoxazole
CH), 7.48–7.46 (m, 2H, ArH), 5.07 (d, 1H, J = 9.2 Hz, H-1), 4.97–
4.91 (m, 2H, H-2, H-3), 3.70 (ddd, 1H, J = 9.0, 3.7, 2.6 Hz, H-5),
3.46–3.17 (m, 3H, H-4, H-6a, H-6b); 13C NMR (DMSO-d6 + D2O,
90 MHz) d (ppm) 163.9 (isoxazole C-5), 155.7 (isoxazole C-3),
155.0 (NHCO), 154.8 (benzothiophen C-2), 144.6, 127.6, 126.6,
124.0, 122.3, 122.0 (Ar), 112.0 (benzothiophen C-3), 109.0 (isoxaz-
ole CH), 80.0 (C-1), 79.2, 77.4, 72.0, 70.0 (C-2–C-5), 61.0 (C-6). Anal.
Calcd for C18H18N2O7S (406.41): C, 53.20; H, 4.46; N, 6.89. Found:
C, 52.81; H, 4.28; N, 7.03.
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isoxazole-5-carboxamide (25)
Prepared by general procedure given in Section 3.3 from 1
(80 mg, 0.139 mmol) for 1 h. Yield: 51 mg (90%) yellow solid
Rf = 0.55 (7:3 CHCl3–MeOH); Mp: 223–225 C [a]D +5.8 (c 0.19
DMSO) 1H NMR (DMSO-d6 + D2O, 360 MHz) d (ppm) 7.90–7.8
(m, 2H, ArH), 7.78 (s, 1H, isoxazole CH), 7.67–7.51 (m, 2H, ArH
4.78 (t, 1H, J = 9.3, 9.3 Hz, H-1), 4.60–4.44 (m, 2H, H-2, H-3
3.54–3.31 (m, 3H, H-6a, H-6b, H-4), 3.22 (ddd, 1H, J = 9.3, 4.
2.3 Hz, H-5); 13C NMR (DMSO-d6 + D2O, 90 MHz) d (ppm) 166.
(isoxazole C-5), 161.9 (isoxazole C-3), 160.3 (benzothiazole C-2
158.9 (NHCO), 150.4, 136.5, 127.3, 126.3, 125.5, 123.2 (Ar), 108.
(isoxazole CH), 81.8 (C-1), 73.6, 71.5, 70.9, 69.7 (C-2–C-5), 62.
(C-6). Anal. Calcd for C17H17N3O7S (407.40): C, 50.12; H, 4.21; N
10.31. Found: C, 49.72; H, 4.03; N, 10.50.
3.5.13. N-(b-D-Glucopyranosyl)-3-(indol-2-yl)-isoxazole-5-
carboxamide (26)
Prepared by general procedure given in Section 3.3 from 1
(100 mg, 0.179 mmol) for 2 h. Yield: 53 mg (76%) yellow oil.
Rf = 0.45 (7:3 CHCl3–MeOH) [a]D +1 (c 0.10, DMSO) 1H NMR
(DMSO-d6 + D2O, 360 MHz) d (ppm) 7.61–7.51 (m, 3H, ArH, isoxaz-
ole CH), 7.35–7.19 (m, 2H, ArH, indol CH), 4.97 (d, 1H, J = 10.6 Hz,
H-1), 3.50–3.07 (m, 6H, H-2, H-3, H-4, H-5, H-6a, H-6b); 13C NMR
(DMSO-d6 + D2O, 90 MHz) d (ppm) 164.0 (isoxazole C-5), 156.8
(isoxazole C-3), 155.4 (NHCO), 147.9, 136.0, 132.3, 125.9, 123.6,
121.5, 118.9 (Ar, indol C-2), 113.3, 110.2 (isoxazole CH, indol CH),
80.6 (C-1), 79.9, 77.7, 73.0, 70.3 (C-2–C-5), 61.6 (C-6). Anal. Calcd
620for C18H19N3O7 (389.36): C, 55.53; H, 4.92; N, 10.79. Found: C,
55.13; H, 4.73; N, 10.93.
3.5.14. N-(b-D-Glucopyranosyl)-3-(indol-3-yl)-isoxazole-5-
carboxamide (27)
Prepared by general procedure given in Section 3.3 from 20
(100 mg, 0.179 mmol) for 1.5 h. Yield: 49 mg (70%) yellow oil.
Rf = 0.40 (7:3 CHCl3–MeOH) [a]D +3 (c 0.10, DMSO) 1H NMR
(DMSO-d6 + D2O, 360 MHz) d (ppm) 7.90 (s, 1H, isoxazole CH),
7.60–7.42 (m, 2H, ArH), 7.34–7.02 (m, 3H, ArH, indol CH), 4.96 (d,
1H, J = 9.2 Hz, H-1), 3.53–3.12 (m, 6H, H-2, H-3, H-4, H-5, H-6a,
630H-6b); 13C NMR (DMSO-d6 + D2O, 90 MHz) d (ppm) 163.6 (isoxaz-
ole C-5), 157.2 (isoxazole C-3), 156.0 (NHCO), 139.1, 133.0, 129.8,
125.6, 124.0, 122.0, 119.1 (Ar, indol C-2), 111.9, 107.3 (isoxazole
CH, indol CH), 80.2 (C-1), 79.7, 78.2, 72.4, 69.9 (C-2–C-5), 61.0 (C-
6). Anal. Calcd for C18H19N3O7 (389.36): C, 55.53; H, 4.92; N,
10.79. Found: C, 55.25; H, 4.69; N, 10.88.
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